citalopram has been researched along with Hepatic Encephalopathy in 4 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Hepatic Encephalopathy: A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the present study, effects of citalopram (CIT) on brain 5-hydroxytryptamine (5-HT) release in experimental chronic hepatic encephalopathy (HE) were investigated." | 7.69 | Effect of citalopram on brain serotonin release in experimental hepatic encephalopathy: implications for thymoleptic drug safety in liver insufficiency. ( Apelqvist, G; Bengtsson, F; Bergqvist, PB; Hjorth, S; Wikell, C, 1997) |
| "Citalopram treatment resulted in elevated behavioural activity in the PCS rats during night, indicative of an improved entrainment to the light-dark cycle, whereas no behavioural effect could be observed in sham rats." | 5.33 | Sustained citalopram treatment in experimental hepatic encephalopathy: effects on entrainment to the light-dark cycle and melatonin. ( Ahlner, J; Apelqvist, G; Bengtsson, F; Carlsson, B; Kugelberg, FC, 2006) |
| "Latent or manifest chronic hepatic encephalopathy (HE) symptomatology often includes affective symptoms." | 5.30 | Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges. ( Andersson, G; Apelqvist, G; Bengtsson, F; Bergqvist, PB; Hindfelt, B; Wikell, C, 1999) |
| "In the present study, effects of citalopram (CIT) on brain 5-hydroxytryptamine (5-HT) release in experimental chronic hepatic encephalopathy (HE) were investigated." | 3.69 | Effect of citalopram on brain serotonin release in experimental hepatic encephalopathy: implications for thymoleptic drug safety in liver insufficiency. ( Apelqvist, G; Bengtsson, F; Bergqvist, PB; Hjorth, S; Wikell, C, 1997) |
| "Citalopram treatment resulted in elevated behavioural activity in the PCS rats during night, indicative of an improved entrainment to the light-dark cycle, whereas no behavioural effect could be observed in sham rats." | 1.33 | Sustained citalopram treatment in experimental hepatic encephalopathy: effects on entrainment to the light-dark cycle and melatonin. ( Ahlner, J; Apelqvist, G; Bengtsson, F; Carlsson, B; Kugelberg, FC, 2006) |
| "Latent or manifest chronic hepatic encephalopathy (HE) symptomatology often includes affective symptoms." | 1.30 | Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges. ( Andersson, G; Apelqvist, G; Bengtsson, F; Bergqvist, PB; Hindfelt, B; Wikell, C, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kugelberg, FC | 1 |
| Apelqvist, G | 3 |
| Carlsson, B | 1 |
| Ahlner, J | 1 |
| Bengtsson, F | 3 |
| Bergqvist, PB | 2 |
| Wikell, C | 2 |
| Hjorth, S | 1 |
| Hindfelt, B | 1 |
| Andersson, G | 1 |
| Michalak, A | 1 |
| Chatauret, N | 1 |
| Butterworth, RF | 1 |
4 other studies available for citalopram and Hepatic Encephalopathy
| Article | Year |
|---|---|
Sustained citalopram treatment in experimental hepatic encephalopathy: effects on entrainment to the light-dark cycle and melatonin.
Topics: Animals; Antidepressive Agents; Circadian Rhythm; Citalopram; Darkness; Dose-Response Relationship, | 2006 |
Effect of citalopram on brain serotonin release in experimental hepatic encephalopathy: implications for thymoleptic drug safety in liver insufficiency.
Topics: Animals; Antidepressive Agents; Biotransformation; Brain Chemistry; Citalopram; Extracellular Space; | 1997 |
Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Chronic D | 1999 |
Evidence for a serotonin transporter deficit in experimental acute liver failure.
Topics: Acute Disease; Animals; Binding Sites; Carrier Proteins; Citalopram; Hepatic Encephalopathy; Hydroxy | 2001 |